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Results: There were 153 patients: 45 (29%) EGFR+ and 108 (71%) 
EGFR WT. The median age was 66 years (range, 38-88). The 
population was composed of 38 (25%) Asian ethnicity, 54 (35%) 
never-smokers, and 97 (63%) female sex. The maximal diameter 
of the primary tumour on PET imaging was no different between 
the two EGFR cohorts (mean 4.0 versus 4.0 cm; p = 0.9). The 
SUVmax ranged from 1.1 to 28.9. There was no difference in 
SUVmax between EGFR+ and EGFR WT cohorts (mean 10.4 versus 
10.6; p = 0.9). There was a significant correlation between larger 
tumour size and higher SUVmax (r = 0.47; p < 0.01). Median 
survival was significantly longer for the EGFR+ cohort (28.4 
versus 14.0 months; p = 0.02). On multivariate analysis, when 
accounting for tumour size, SUVmax was not a significant factor 
for survival (p = 0.8). 
Conclusions: In our study there was no correlation between FDG-
PET uptake and EGFR mutation status in patients with metastatic 
NSCLC. The SUVmax cannot be used to predict EGFR mutation 
status or survival. 
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Purpose: Decades of reported experience with low dose rate 
penile brachytherapy have demonstrated local tumour control 
rates and penile preservation of 70-85% at 5-10 years with 
acceptable side effects. Manual source loading is not available in 
most centres in North America so there is a need to explore the 
transition to high-dose rate (HDR) automated afterloading for 
treatment delivery. Dose homogeneity parameters and 
fractionation schemes need to be developed and validated. 
Methods and Materials: Prior experience in interstitial 
template-based penile brachytherapy using either manually 
loaded Ir-192 wire or Pulse Dose Rate after-loading was the basis 
for transitioning to an HDR treatment schema using Varian 
GammaMed. Templates with 15-18 mm spacing designed for LDR 
brachytherapy were found to be not ideal for HDR delivery. 
Spacing was initially 17 mm but was decreased sequentially to 9 
mm. A new design of template was created with holes drilled 
every 3 mm so that inter-plane and inter-needle spacing could 
be generally 9 mm but increased to 12 around the urethra. Four 
patients had a 3-plane implant and two patients had 2 planes. 6-
13 catheters were used. Fractionation was 4200/12 for three 
patients, 4500/12, 5300/17 and 3840/12 for one patient each, 
with fraction sizes of 3.12-3.75 Gy, given bid six hours apart. PTV 
ranged from 4 to 57 cc, median V100: 96% (88-99), V125 75% (40-
98), V150 42% (18-89), V200 16.8% (4.7-32). 
Results: From November 2009 to December 2012 six patients 
with biopsy-proven SCC of the glans penis received HDR 
interstitial brachytherapy. Age range 33-77, Stage T1:2 and T2: 
4, pN0:1, cN0: 5, Grade was MD in five and PD in one. Median 
follow up is 55 months (31-73). All six patients are NED, although 
one patient with local and regional failure was salvaged with 
partial penectomy and left groin dissection. Toxicity was 
considerable. Five patients experienced painful necrosis with 
four requiring Hyperbaric oxygen treatment. One of these 
subsequently had partial penectomy for recurrence; the other 
four eventually healed. Three patients had severe meatal 
stenosis, one requiring a temporary suprapubic tube for 10 
months (now resolved) and one requiring a permanent perineal 
urostomy. Two patients remain potent. Toxicity was related to 
greater needle spacing, larger fraction size, larger PTV volume 
and excessive inhomogeneity. 9-12 mm is now considered ideal 
spacing, with fraction size close to 3 Gy, and with V125 ~ 40%, 
V150~20% and V200 ~5% . The final patient, whose dosimetry 
followed these parameters, was the only one who was 
complication free but also had the smallest PTV. Whether 
following these dosimetric guidelines will permit safe 
implantation of larger volumes remains to be determined. 
Conclusions: HDR penile brachytherapy is effective and can be 
delivered safely (as evidenced by two recent reports from 
Sharma et al. and Kellas-Sleczka et al.) but attention must be 
paid to catheter spacing, fractionation and implant homogeneity 
parameters. 
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Purpose: To estimate the rate of biochemical recurrence in 
prostate cancer treated with intraoperatively planned, low dose 
rate, prostate brachytherapy using an automated delivery system 
(IO-LDRB). 
Methods and Materials: Patients treated with IO-LDRB as a single 
modality treatment for low or low-tier intermediate-risk 
prostate cancer at three Canadian centres between December 
1997 and August 2015 were pooled for analysis. Retrospective or 
prospective databases were maintained at each centre. For this 
analysis the datasets were amalgamated and analyzed using the 
R programming language build 3.1.3 (www.r-project.org). 
Shapiro-Wilks tests of normality, descriptive statistics and 
Kaplan-Meier survival estimates of biochemical relapse-free 
survival (bRFS) were employed for analysis. 
Results: 3286 patients with a median follow up of 44 months (0.0 
- 212.8) and median biochemical follow up of 40.0 months were 
analyzed. Median age for treated patients was 65 (42-84) years. 
In these patients, median initial PSA was 5.6 ng/mL (0.03 – 23.8), 
2390 (74%) were T1 and 862 (26%) were T2, and initial Gleason 
Sum was 6 in 2383 (73%) and 7 in 810 (25%). Most patients had 
low volume disease: median % positive biopsy tissue 5.0% (0.1-
90.0), normal gland volumes: median 34.2cc (10.9 – 77.8) and 
few urinary symptoms: median pre-implant AUA was 5 (0 -33). 
387 (11.8%) of patients received hormones for a median of 3.0 
months (0.5-32.1) prior to implant. Median seed activity was 
0.437 mCi (0.10 – 0.68), D90 was 186.7 Gy (97.0 – 273.0) and V100 
was 99.37% (60.52 – 100.0). In follow up, median last PSA value 
was 0.13 (0.0 – 901.0) and available in 3192 patients. Biochemical 
failure was observed in 139 patients (5.8%) and median time to 
failure was 44.0 months (0.0 – 218.8). Five- and 10-year 
predicted bRFS were 96% and 86%, respectively. Seventy-four 
deaths were observed from all causes and of those, no death was 
attributable to prostate cancer. 
Conclusions: This is the largest cohort of patients treated with 
IO-LDRB and demonstrates it to be an effective treatment option 
for patients with low and low-tier intermediate-risk prostate 
cancer. Rates of biochemical relapse were low several years 
post-treatment. 
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Purpose: EEC is a rare disease entity with only a handful of 
patients diagnosed every year at most large centres treating 
esophageal cancer. Standard treatments for EEC include 
endoscopic mucosal resection, surgery (S) or chemoradiation 
(CRT). Patients are often not candidate for S or CRT because of 
their comorbidities or for EMR because of extent of tumour. 
Brachytherapy in these instances can give high doses of RT locally 
to the tumour. We present our experience using Radical 
Brachytherapy (RBT) alone in EEC. 
